Partnering with Leaders in Cancer Immunotherapy
As with many transformative efforts, changing the paradigm of cancer treatment requires partnerships with other leaders in the field to develop next-generation technologies and products. Guided by this principle, we are collaborating with world-renowned academic institutions and industry leaders.
Are you interested in partnering with Kite?
We are actively exploring new partnership opportunities focused on enabling technologies and capabilities designed to bring life-saving therapies to patients. Please contact us at email@example.com.
The National Cancer Institute (NCI)
Kite and NCI are in a Cooperative Research and Development Agreement to develop multiple engineered autologous cell therapy product candidates for the treatment of advanced hematological and solid malignancies..
Dr. Steve Rosenberg, Chief of Surgery at the National Cancer Institute, was interviewed by BioCentury TV to discuss his viewpoint and perspectives on recent advances in cancer immunotherapy.
Kite and Daiichi Sankyo established a strategic relationship to develop and commercialize axicabtagene ciloleucel in Japan with the option to license additional Kite product candidates for Japan including KITE-718, Kite’s TCR product candidate targeting MAGE-A3/A6 and certain other product candidates.
The Netherlands Cancer Institute (NKI)
Kite and NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors.
Dr. Ton Schumacher, Chief Scientific Officer of Kite Pharma EU, is also a Principal Investigator at The Netherlands Cancer Institute, where he also serves as Deputy Director.
The UCLA David Geffen School of Medicine
Several of Kite’s scientific leaders are affiliated with UCLA, and Kite also entered into a license agreement to acquire rights to develop and commercialize technology for the development of off-the-shelf allogeneic T-cell therapies from renewable pluripotent stem cells.